Investigate New Strategies and Opportunities in the Cardiovascular Disease Biomarker and Diagnostics Market
(http://www.researchandmarkets.com/research/ae4771/blood_biomarkers_a) has announced the addition of Decision Resources, Inc.'s new report "Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease" to their offering.
Introduction
Demographic and cost data provide clear reasons for pharmaceutical industry investment in CVD biomarkers and diagnostics. CVDs are highly prevalent and potentially lethal diseases with high treatment costs; biomarkers offer the potential to decrease these costs by helping physicians to more efficiently manage CVD patients.
Get the Answers You Need to Shape Your Strategy
Debate surrounds the comparative value of new cardiac biomarkers versus established markers for risk assessment and prognosis. Have clinical studies supported the value of new cardiac biomarkers? Which
new biomarkers have been shown to add independent capabilities for risk assessment and prognosis?
- The 2007 National Academy of Clinical Biochemistry (NACB) guidelines provide the most up-to-date thinking in biochemical diagnostic procedures for CVDs. Do these new guidelines support the use and value of cardiac biomarkers? Have these new guidelines seen aggressive uptake in the medical community?
- Point-of-care cardiac tests offer their own unique benefits to CVD care, but many debate their correlation with central laboratory tests. What are the economic benefits of these POC tests? Are POC tests proving to be better than central lab tests?
Scope
- Focus on use of biomarkers in three key CVDs: coronary heart disease (CHD), acute coronary syndrome (ACS), and chronic heart failure (CHF).
- Review of imaging technologies used for CVD: magnetic resonance imaging, computed tomography, positron emission tomography, single photon electron computed tomography, and near infrared fluorescence.
- Targeting of disease progression and risk stratification: genetic testing in CHD, biomarkers of plaque instability, serum markers for ACS and CHF.
- POC testing: economic benefits, comparison with central lab tests, top competitors.
- Strategic business models for CVD diagnostics: mergers and acquisitions, licensing activities.
- Investment considerations in CVD diagnostics: clinical validation and acceptance of new cardiac markers, need to control healthcare costs, debate over added value of new markers, increased investment in research, POC opportunities, improved modalities.
Key Topics Covered:
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Value of Biomarkers and Diagnostics in Cardiovascular Disease
- New Guidelines for Cardiac Biomarkers
- Targeting Disease Progression
- Genetic Testing in Coronary Heart Disease
- Biomarkers of Plaque Instability
- sCD40 Ligand
- Myeloperoxidase
- Placental Growth Factor
- Pregnancy-Associated Plasma Protein-A
- Targeting Risk Stratification
- Serum Markers for Acute Coronary Syndrome
- Cardiac Troponins
- C-Reactive Protein
- Heart Fatty Acid Binding Protein
- Serum Markers for Chronic Heart Failure
- Brain Natriuretic Peptide
- ST2
- Point-of-Care Testing in Cardiovascular Disease
- POC Tests Offer Economic Benefits
- POC Tests Versus Central Laboratory Tests
- Capturing Market Share
- Diagnostic Imaging Technologies for Cardiovascular Diseases
- Need for Noninvasive Diagnostic Imaging Procedures
- Magnetic Resonance Imaging
- Computed Tomography
- Nuclear Medicine
- Positron Emission Tomography
- Single Photon Emission Computed Tomography
- Near Infrared Fluorescence
- Strategic Business Models for Cardiovascular Diagnostics
- Mergers and Acquisitions
- Licensing Activities
- Issues to Consider When Investing in Cardiac Biomarker and
Diagnostics R&D
- Clinical Validation and Acceptance of New Cardiac Markers
- Need to Control Spiraling Healthcare Costs
- Debate Over Value of New Cardiac Biomarkers in Risk Assessment
- Greater Investment in Biomarker Research
- Opportunities in Cardiac POC Testing
- Improved Diagnostic Imaging Modalities
- CVD Biomarkers
Companies Mentioned:
- Abbott Diagnostics
- ACS Biomarker
- Amersham Biosciences
-
- AstraZeneca
- Baxter
- Bayer Diagnostics
- Beckman Coulter
- Behring Diagnostics
- BG Medicine
- BioMerieux
- Bio-Rad
- Bio-Rad Pasteur
- Biosite
- Cholestech
- Competitive Technologies
- Critical Diagnostics
- Dade Behring
- Dainippon Sumitomo
- deCode Genetics
- Diagnostic Products
- DuPont
- GE Healthcare
- Geymonat SpA
- Illumina
- Innovectis
-
- Johnson & Johnson
- Lab21
- LabCorp
- Matritech
- Meso Scale Discovery
- Nanogen
- Ortho Clinical Diagnostics
- Philips
-
- Prognostix
- Response Biomedical
- Roche Diagnostics
- Scios
- Shionogi
- Siemens Medical Solutions
- Singulex
- Spectral Diagnostics
- Third Wave Technologies
- ThromboGenics
- Toshiba
For more information visit here
Research and Markets
Laura Wood, Senior Manager
Fax from
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com
Copyright Business Wire 2008